An interventional study of catheter insertion in Premature Birth, sponsored by University Hospital, Clermont-Ferrand. Not yet recruiting at 1 site in France. Open to participants aged Up to 3 Months, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-02-06.
Sponsored by University Hospital, Clermont-Ferrand · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 205 studies in Premature Birth with a site in France — 40 open to participants now, 46 under way, 2 of them phase 3. Premature Birth · France.
Among the 205 studies in Premature Birth with a site in France, this one is the 53rd largest by planned enrollment of the 104 interventional ones that give a count, is one of 11 that started in 2025, is one of 80 with no phase, reaches primary completion later than 29 of the 45 other live ones, and was the 187th registered.
2,557 studies on the registry are indexed under Premature Birth; 504 are open to participants now.
Browse Premature Birth studies →40 of the 205 studies in Premature Birth with a site in France are open now. Recruiting first, the newest first:
Institut National de la Santé Et de la Recherche Médicale, France · Sites in France
Ages up to 5 mo · Healthy volunteers
University Hospital, Strasbourg, France · Sites in France
Ages 0 mo–18 mo
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 6 yrs–78 mo
Bioprojet · Sites in France
Ages 18–50 · Men only
Hospices Civils de Lyon · Sites in France
Ages up to 32 wk
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 318 Premature Birth studies recruiting now, 88 (28%) set no upper age limit and 226 (71%) stop at 75 or younger; 243 take children under 18; 104 take healthy volunteers.
This study: Up to 3 Months · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
205 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 6 · Phase 3 12 · Phase 4 10
First in 1997; this study’s year is marked. 11 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 96 is above the median of 84 across 1,670 interventional studies indexed under Premature Birth.
Median enrollment 98 across the 104 interventional studies, 130 across the 99 observational. Of the 139 that completed or were terminated, 2 (1%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 205 have an industry lead sponsor. The 10 most frequent:
University Hospital, Clermont-Ferrand is the lead sponsor of 859 studies on the registry; 177 are open to participants now.
University Hospital, Clermont-Ferrand has 7 studies filed under Premature Birth — fewer than ten, so there is no comparison to draw.
16 of the studies in Premature Birth with a site in France that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03976063Phase 3Assistance Publique - Hôpitaux de ParisTocolysis in the Management of Preterm Premature Rupture of Membranes Before 34 Weeks of Gestation | 2026-11 |
| NCT04372953Murdoch Childrens Research InstitutePositive End-Expiratory Pressure (PEEP) Levels During Resuscitation of Preterm Infants at Birth (The POLAR Trial). | 2026-11-30 |
| NCT06064825Institut National de la Santé Et de la Recherche Médicale, FranceLong Term Follow-up of the TREOCAPA Study (TREOCAPA-LT) | 2026-12 |
| NCT07047404BioprojetProof of Concept Study on BP1.4979 Effect on Primary Premature Ejaculation | 2026-12 |
| NCT07169110University Hospital, ToulouseStudy of the Interprofessional Reproducibility of a Clinical Observation Scale for the Development of Very Premature Infants | 2026-12-30 |
Add all 16 to your calendar (.ics) → With an account.
Among the 205 studies in Premature Birth with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To meet the needs of newborns in neonatal intensive care and ensure long-term venous access, a percutaneous central venous catheter (KTEC) is inserted. According to the recommendations of the French Society of Hospital Hygiene, the placement of this device is the responsibility of a medical professional. It may require several attempts to ensure the success of the procedure.
The pain associated with the needle insertion is generally controlled, but with repeated attempts, the newborn may become agitated, cry, and be difficult to calm. The study by Courtois et al. showed that pain in infants under 45 weeks of gestational age increased with the number of attempts. Acute and repeated pain in newborns can lead to trauma and disturbances in psychological, cognitive, and motor development.
In the neonatal intensive care unit (NICU) at the University Hospital of Clermont-Ferrand, the procedure is performed by the physician alone (i.e., "two hands"), whereas in other NICUs in France, the procedure is systematically performed by a nurse/physician team (i.e., "four hands"). However, no comparative study has been conducted to date to assess the impact of this "four hands" approach on the number of needle attempts and the pain experienced by the newborn.
The investogator hypothesize that the training and participation of the nurse (pediatric nurse) during the placement of the KTEC, in collaboration with the physician, could reduce the number of needle attempts and the newborn's pain. Therefore, the investigator aim to conduct a randomized, monocentric pilot study in the neonatal intensive care unit at the University Hospital of Clermont-Ferrand.
In the neonatal intensive care unit (NICU) of the University Hospital of Clermont-Ferrand (63), the study will begin with the training of a group of nurse practitioners (I(P)DE) to perform KTEC insertions in pairs over a six-month period. After this training, if a KTEC insertion is required, the investigator will ask the parents or guardians of eligible newborns for their consent to participate in the IPICAVE study (pre-inclusion visit).
If they agree, inclusion/randomization will take place after the parents or legal guardians sign the informed consent form for study participation.
The inclusion period will last for 18 months, and the study participation for each newborn will begin with the first needle insertion during the procedure and end at the conclusion of the dressing change after successful KTEC insertion or upon the last needle insertion if the attempt fails. During the KTEC insertion, the responsible I(P)DE will complete a data collection form to assess the various study criteria.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
At D1, on the first attempt, the KTEC will be inserted by an I(P)DE/physician pair served by the nurse in charge of the child (whatever their level of experience) using the standard method, with no limit to the number of injections. At D2, if KTEC insertion fails at D1, a second attempt will be made, respecting the newborn's randomization arm. This second attempt must be carried out by an I(P)DE/doctor pair, with the nurse having a minimum of three years' seniority in a neonatal intensive care unit, and whose expertise will ensure successful insertion, with the number of injections limited to five. At D3, in the event of a further failure at D2, a third and final attempt will be made by a senior doctor, with no limit on the number of injections (to encourage success), in line with current department practice. Translated with DeepL.com (free version)
Procedure: catheter insertion
At D1, on the first attempt, the KTEC will be inserted by the doctor alone (junior or senior, depending on availability), assisted by the nurse responsible for the child, using the standard method, with no limit on the number of injections. On D2, if KTEC insertion fails on D1, a second attempt will be made, respecting the newborn's randomization arm. This second attempt must be made by a senior doctor in the department, whose expertise will help ensure successful insertion, with the number of injections limited to five. At D3, in the event of a further failure at D2, a third and final attempt will be made by another senior doctor, with no limit on the number of injections (to encourage success), in line with the department's current practice. Translated with DeepL.com (free version)
Procedure: catheter insertion
success of catheter insertion
Successfull of KTEC insertion
Total number of injections until successful KTEC insertion.
Time frame: within day 3
success rate of the procedure.
Success or failure of KTEC insertion.
Time frame: within day 3
pain evaluation
Average and maximum pain during injections, measured by hetero-evaluation scales
Time frame: within day 3
number of insertion attempts in cases of previous failure
Total number of previous unsuccessful placement attempts
Time frame: within day 3
procedure time
procedure time in minutes
Time frame: within day 3
Study the factors associated with the total number of bites
number of bites according to the occurrence or non-occurrence of state of consciousness (awake or sedated newborn)
Time frame: within day 3
Study factors associated with average and maximum pain in newborns
average and maximum pain according to state of gestational age (in weeks of amenorrhea: ˂29 , 29 to 32, 33 to 36, 37 to 42, and \>42)
Time frame: within day 3
hemoglobin levels
Percentage change in hemoglobin between two consecutive days (dependent variable) and number of injections performed between the two hemoglobin measurements (independent variable)
Time frame: within day 3
Study the factors associated with the total number of bites
number of bites according to catheter type (Premicath, Epicutaneocave, Nutriline twinflow)
Time frame: within day 3
Study factors associated with average and maximum pain in newborns
average and maximum pain according to insertion site (left/right upper limb, left/right lower limb, skull)
Time frame: within day 3
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Jul 2025; primary completion for Feb 2027, 19 months later.
Of 746 non-industry interventional studies with no phase under Premature Birth, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 47. This study's planned 19 months is below that.
Counting every sponsor, half of 764 studies reached it within 24 months; a quarter within 12 and three quarters within 47.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Clermont-Ferrand →